Merck Millipore and Proteomics International collaborate over protein biomarkers

Merck Millipore has announced a collaboration with Proteomics International to validate biomarkers related to diabetic nephropathy.

The union will allow Proteomics International to assess its 13 newly identified putative protein biomarkers, that include proteins involved in metabolism, inflammation and oxidative stress, using Merck Millipore’s multiplex immunoassays. This will mean that, once validated, the biomarkers could be used to effectively monitor the progression and prognosis of kidney disease in patients with diabetes.

Jehangir Mistry, PhD, director of R&D at Merck Millipore, said, “We expect this opportunity will enable Merck Millipore to expand our substantial portfolio of Elisa and Milliplex multiplexed-bead based assays for diabetes and metabolic disease biomarkers.”

Richard Lipscombe, PhD, managing director of Proteomics International, commented, “We chose to partner with Merck Millipore because of their extensive portfolio of developed protein biomarkers and custom assay development expertise. We are very excited to be working with them to progress our initial discovery of these biomarkers that could improve diagnosis and health outcomes on such a large scale.”

For more information please visit ref="http://www.millipore.com">www.millipore.com